SYBLEU (SYBE) 10-Q/A 17 Jan 23 2022 Q2 Quarterly report (amended) Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2022	Jan. 12, 2023
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	THIS AMENDMENT NO.1 TO SYBLEU INC’S (THE “COMPANY”) FORM 10-Q FOR THE PERIOD ENDED DECEMBER 31, 2022 (“(“ORIGINAL FILING”) IS BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF THE ORIGINAL FILING: SIGNATURES
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	333-248059
Entity Registrant Name	SYBLEU INC.
Entity Central Index Key	0001818674
Entity Tax Identification Number	85-1412307
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	1034 Throggs Neck Expressway
Entity Address, City or Town	Bronx
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10465
City Area Code	(718)
Local Phone Number	795-7790
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,304,492

CONDENSED BALANCE SHEETS (Unaud

CONDENSED BALANCE SHEETS (Unaudited) - USD ($)	Dec. 31, 2022	Jun. 30, 2022
CURRENT ASSETS
Cash	$ 36,848	$ 66,850
Prepaid Expenses	16,236	0
Total Current Assets	53,084	66,850
OTHER ASSETS
Investment Securities	2,200	9,529
Prepaid Expenses ( Long Term)	5,715
Total Other Assets	7,915	9,529
TOTAL ASSETS	60,999	76,379
Current Liabilities:
Income Taxes Payable	10,935	10,935
Notes Payable	140,000	140,000
Notes Payable, Related Party	0	0
Expenses Accrued but Unpaid	150	452
Interest Accrued but Unpaid	20,196	13,253
Total Current Liabilities	171,281	164,640
Long Term Liabilities:
Unearned Income	155,801	161,699
Total Liabilities	327,082	326,338
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001; 10,418,000 shares issued and outstanding as of June 30, 2022 and 10,304,492 shares issued and outstanding  as of December 31, 2022	1,031	1,042
Additional Paid in capital	122,214	100,049
Retained Earnings (Deficit )	(389,328)	(351,051)
Total Stockholders' Equity (Deficit)	(266,083)	(249,960)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 60,999	$ 76,379

CONDENSED BALANCE SHEETS (Una_2

CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2022	Jun. 30, 2022
Statement of Financial Position [Abstract]
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued	10,304,492	10,418,000
Common Stock, Shares, Outstanding	10,304,492	10,418,000

CONDENSED STATEMENT OF OPERATIO

CONDENSED STATEMENT OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
REVENUES
License Fees	$ 2,948	$ 2,949	$ 5,897	$ 5,898
TOTAL REVENUES	2,948	2,949	5,897	5,898
Research and Development:
Staff Expenses	345	0	345
Consulting Costs	0
Patent Application Costs	0	3,800		4,700
Total Research and Development	345	3,800	345	4,700
General and Administrative:
Transfer Agency Fees	691	614	1,332	982
Other General and Administrative Expenses	1,404	5,891	2,433	8,704
Total General and Administrative	2,095	6,505	3,765	9,687
Consulting:
Accounting	5,500	5,400	16,500	21,600
Total Consulting	5,500	5,400	16,500	21,600
Total Costs and Expenses	7,940	15,705	20,610	35,987
OPERATING Income( LOSS)	(4,992)	(12,756)	(14,713)	(30,089)
OTHER INCOME AND EXPENSES
Unrealized Gain ( Loss) on Investment Securities	(790)	(44,005)	(7,329)	(158,925)
Stock Cancellation Expense	(9,294)	0	(9,294)
Interest Income( Expense)	(3,451)	(4,990)	(6,941)	(5,045)
TOTAL OTHER INCOME ( EXPENSES)	(13,535)	(48,995)	(23,564)	(163,970)
NET INCOME ( LOSS) before taxes	(18,527)	(61,751)	(38,277)	(194,059)
Provision for Inocme Taxes			0
NET INCOME ( LOSS)	$ (18,527)	$ (61,751)	$ (38,277)	$ (194,059)
BASIC AND FULLY DILUTED LOSS PER SHARE	$ 0	$ (0.01)	$ 0	$ (0.02)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	10,394,301	10,418,000	10,406,215	10,418,000

CONDENSED STATEMENTS OF SHAREH

CONDENSED STATEMENTS OF SHAREHOLDERS EQUITY (DEFICIT) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2021	$ 1,042	$ 100,049	$ (105,705)	$ (4,614)
Beginning balance, shares at Jun. 30, 2021	10,418,000
Net Loss			(132,307)	(132,307)
Ending balance, value at Sep. 30, 2021	$ 1,042	100,049	(238,012)	(136,921)
Ending balance, shares at Sep. 30, 2021	10,418,000
Net Loss			(61,751)	(61,751)
Ending balance, value at Dec. 31, 2021	$ 1,042	100,049	(299,763)	(198,672)
Ending balance, shares at Dec. 31, 2021	10,418,000
Beginning balance, value at Jun. 30, 2022	$ 1,042	100,049	(351,051)	(249,960)
Beginning balance, shares at Jun. 30, 2022	10,418,000
Net Loss			(19,750)	(19,750)
Ending balance, value at Sep. 30, 2022	$ 1,042	100,049	(370,801)	(269,710)
Ending balance, shares at Sep. 30, 2022	10,418,000
Beginning balance, value at Jun. 30, 2022	$ 1,042	100,049	(351,051)	(249,960)
Beginning balance, shares at Jun. 30, 2022	10,418,000
Ending balance, value at Dec. 31, 2022	$ 1,031	122,214	(389,328)	(266,083)
Ending balance, shares at Dec. 31, 2022	10,304,492
Beginning balance, value at Sep. 30, 2022	$ 1,042	100,049	(370,801)	(269,710)
Beginning balance, shares at Sep. 30, 2022	10,418,000
Cancellation of shares 12/13/2022	$ (611)	(95)		(706)
Cancellation of shares, shares	(6,113,508)
Issuance of shares for services 12/12/2022	$ 600	22,260		22,860
Issuance of shares for services, shares	6,000,000
Net Loss			(18,527)	(18,527)
Ending balance, value at Dec. 31, 2022	$ 1,031	$ 122,214	$ (389,328)	$ (266,083)
Ending balance, shares at Dec. 31, 2022	10,304,492

CONDENSED STATEMENT OF CASH FLO

CONDENSED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ (38,277)	$ (194,058)
Adjustments to reconcile net Income (loss) to net cash
Common Stock Issued for payment of expenses	909
Changes in Operating Assets and Liabilities
Increase (Decrease) in Accrued Expenses	6,640	9,008
Increase( Decrease) in Unearned Income	(5,897)	(5,898)
Decrease in Common Stock	(611)
Decrease in Additional Paid in Capital	(95)
Unrealized Loss ( Gain) in Investment Securities	7,329	158,925
Net Cash provided by (used) in Operating Activities	(30,002)	(32,023)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase ( Decrease)   in Notes Payable, Related Parties		(8,919)
Increase ( Decrease)   in Notes Payable		140,000
Net Cash provided by (used) in Financing Activities	0	131,081
Net Increase (Decrease) in Cash	(30,002)	99,058
Cash at Beginning of Period	66,850	14,297
Cash at End of Period	36,848	113,355
Supplemental Cash Flow Information:
Interest Paid	0	0
Income Taxes Paid	$ 0	$ 0

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming. The Company intends to engage primarily in the development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end. B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application. F. STOCK BASED COMPENSATION Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the quarter ended December 31, 2022 6,000,000 In determining Fair Value for shares issued to employees an asset based valuation method was utilized , specifically Enterprise Value(Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized. Schedule of valuation method of fair value of unvested shares Fair Value of Intellectual Property $ 35,490 Securities $ 3,771 Notes Payable $ 140,000 Accrued Interest $ 19,504 Taxes Payable $ 10,935 Less Total Debt $ (170,439 ) Portion of Enterprise Value available to shareholders $ 39,261 Fair Value per share $ 0.00381 Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable During the quarter ended December 31, 2022 no Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete. G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December 31, 2022 the Company had no The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of December 31, 2022.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Dec. 31, 2022
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements. On February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as "lessees," to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This guidance is not expected to have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting.

GOING CONCERN

GOING CONCERN	6 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated net losses of $ 389,328 Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

RELATED PARTY TRANSACTIONS.

RELATED PARTY TRANSACTIONS.	6 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS.	NOTE 4. RELATED PARTY TRANSACTIONS. The Company utilizes approximately 500 square feet of office space at 1034 Throggs Neck Expressway, Bronx NY 10465 provided to the Company by Joseph G. Vaini, the Company’s sole officer and director, on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space. On January 8, 2023 the Company entered into an agreement with Joanne Vaini whereby Joanne Vaini agreed to provide bookkeeping services for the Company for the period beginning January 9, 2023 and ending July 9, 2024 (“Agreement”) for total consideration consisting of $ 15,000

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTES PAYABLE Schedule of related party debt Bostonia Partners 140,000 Notes Payable, as of December 31, 2022 $ 140,000 $ 10,000 10 September 20,2022 $ 30,000 10 September 30,2022 $ 100,000 10 October 5,2022

INVESTMENT SECURITIES

INVESTMENT SECURITIES	6 Months Ended
	Dec. 31, 2022
Schedule of Investments [Abstract]
INVESTMENT SECURITIES	NOTE 6. INVESTMENT SECURITIES On March 11, 2021 the Company was paid 6,500 On December 31, 2022 the Company revalued 6,500 As of December 31, 2022: Schedule Of Common Shares 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or ( Loss) during the quarter ended December 31, 2022 $ 177,450 $ 2,200 $ (175,250 ) $ (790 )

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Dec. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 7. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following class of capital stock as of December 31, 2022: Common stock, $ 0.0001 100,000,000 10,304,492 With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

STOCK ISSUANCES AND CANCELLATIO

STOCK ISSUANCES AND CANCELLATIONS	6 Months Ended
	Dec. 31, 2022
Stock Issuances And Cancellations
STOCK ISSUANCES AND CANCELLATIONS	NOTE 8 . STOCK ISSUANCES AND CANCELLATIONS On December 12, 2022 the Company issued 3,000,000 On December 12, 2022 the Company issued 3,000,000 On December 13, 2022 the Company cancelled 6,113,508 10,000

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
FAIR VALUE OF FINANCIAL INSTRUMENTS	D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
RESEARCH AND DEVELOPMENT COSTS	E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.
STOCK BASED COMPENSATION	F. STOCK BASED COMPENSATION Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the quarter ended December 31, 2022 6,000,000 In determining Fair Value for shares issued to employees an asset based valuation method was utilized , specifically Enterprise Value(Assets Less Cash and Cash Equivalents plus Fair Value of Debt) less Fair Value of Debt. The following inputs were utilized. Schedule of valuation method of fair value of unvested shares Fair Value of Intellectual Property $ 35,490 Securities $ 3,771 Notes Payable $ 140,000 Accrued Interest $ 19,504 Taxes Payable $ 10,935 Less Total Debt $ (170,439 ) Portion of Enterprise Value available to shareholders $ 39,261 Fair Value per share $ 0.00381 Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable During the quarter ended December 31, 2022 no Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete.
INCOME TAXES	G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December 31, 2022 the Company had no The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of December 31, 2022.

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of valuation method of fair value of unvested shares	Schedule of valuation method of fair value of unvested shares Fair Value of Intellectual Property $ 35,490 Securities $ 3,771 Notes Payable $ 140,000 Accrued Interest $ 19,504 Taxes Payable $ 10,935 Less Total Debt $ (170,439 ) Portion of Enterprise Value available to shareholders $ 39,261 Fair Value per share $ 0.00381

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of related party debt	Schedule of related party debt Bostonia Partners 140,000 Notes Payable, as of December 31, 2022 $ 140,000

INVESTMENT SECURITIES (Tables)

INVESTMENT SECURITIES (Tables)	6 Months Ended
	Dec. 31, 2022
Schedule of Investments [Abstract]
Schedule Of Common Shares	Schedule Of Common Shares 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or ( Loss) during the quarter ended December 31, 2022 $ 177,450 $ 2,200 $ (175,250 ) $ (790 )

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2022	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fair Value of Intellectual Property	$ 35,490
Securities	3,771
Notes Payable	140,000	$ 140,000
Accrued Interest	19,504
Taxes Payable	10,935	$ 10,935
Less Total Debt	(170,439)
Portion of Enterprise Value available  to shareholders	$ 39,261
Fair Value per share	$ 0.00381

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	6 Months Ended
	Dec. 31, 2022 USD ($) shares
Defined Benefit Plan Disclosure [Line Items]
Uncertain tax positions | $	$ 0
Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued for compensation	6,000,000
Non Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued for services	0

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	31 Months Ended
	Dec. 31, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income loss	$ 389,328

RELATED PARTY TRANSACTIONS. (De

RELATED PARTY TRANSACTIONS. (Details Narrative)	Jan. 08, 2023 USD ($)
Joanne Vaini [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Total consideration	$ 15,000

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)	Dec. 31, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	$ 140,000
Bostonia Partners [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	$ 140,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)	6 Months Ended
	Dec. 31, 2022 USD ($)
Bostonia Partners [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 10,000
Interest rate	10%
Maturity date	Sep. 20, 2022
Bostonia Partners 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 30,000
Interest rate	10%
Maturity date	Sep. 30, 2022
Bostonia Partners 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 100,000
Interest rate	10%
Maturity date	Oct. 05, 2022

INVESTMENT SECURITIES (Details)

INVESTMENT SECURITIES (Details) - Oncology Pharma Inc [Member]	6 Months Ended
	Dec. 31, 2022 USD ($)
Schedule of Investments [Line Items]
Investment securities, basis	$ 177,450
Investment securities, fair value	2,200
Investment securities, total unrealized losses	(175,250)
Investment securities, net unrealized gain or loss realized	$ (790)

INVESTMENT SECURITIES (Details

INVESTMENT SECURITIES (Details Narrative) - shares		6 Months Ended
	Mar. 11, 2021	Dec. 31, 2022
Oncology Pharma Inc [Member]
Schedule of Investments [Line Items]
Number of shares issued for property dividend	6,500	6,500

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Dec. 31, 2022	Jun. 30, 2022
Equity [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,304,492	10,418,000
Common stock, shares outstanding	10,304,492	10,418,000

STOCK ISSUANCES AND CANCELLAT_2

STOCK ISSUANCES AND CANCELLATIONS (Details Narrative) - USD ($)	Dec. 13, 2022	Dec. 12, 2022
Joseph G Vaini [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued		3,000,000
Harry Lander [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued		3,000,000
David Koos [Member]
Defined Benefit Plan Disclosure [Line Items]
Cancellation of shares	6,113,508
David Koos [Member] | Separation Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Payment on shares	$ 10,000